Abstract
To evaluate the safety and immunogenicity of a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, LBVH0101 (LG Life Sciences, Ltd.), an open-label, single-arm, phase I study was conducted in twenty healthy adults aged 19 years or older. The subjects were followed for 1 month after administration of a single dose of the vaccine and serum anti-PRP antibody was measured before and 1 month after administration. Among 20 vaccinated subjects, each 10 subjects (50%) reported at least one local and systemic adverse event within 7 days after the vaccination, respectively. Most of the local and systemic adverse events were mild in intensity and resolved within 7 days. There was no death or treatment-related serious adverse event. Geometric mean titers (GMTs) of anti-PRP antibody before and 1 month after the vaccination were 0.71 μg/mL (95% Confidence Interval [CI]: 0.32–1.58,) and 70.26 μg/mL (95% CI: 46.65–105.82), respectively, demonstrating the GMT of anti-PRP antibody at post-vaccination was approximately 98 times higher than that of pre-vaccination. Taken together, LBVH0101 appeared to be safe and well-tolerated and showed good immunogenicity in Korean healthy adults.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Coulehan, J. L., Michaels, R. H., Hallowell, C., Schults, R., Welty, T. K., and Kuo, J. S., Epidemiology of Haemophilus influenzae type b disease among Navajo Indians. Public Health Rep., 99, 404–409 (1984).
Ellis, R. W., Perspectives on vaccine development. In Ellis, R. W. and Granoff, D. M. (Eds.). Development and clinical uses of Haemophilus b conjugate vaccines. Marcel Dekker, Inc., New York, pp. 19–35, (1994).
Jung, E. H., Kim, Y. J., Kim, Y. K., Kim, D. H., Seo, J. W., and Lee, H. J., Immunogenicity and safety of a Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T; Hiberix™) in Korean infants. Korean J. Pediat. Infect. Dis., 10, 71–80 (2003).
Käyhty, H., Peltola, H., Karanko, V., and Makela P. H., The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis., 147, 1100 (1983).
Kim, J. S., Cho, S. B., Lee, H. R., Park, S. K., and Hwang, P. H., Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T) in Korean infants. Korean J. Infect. Dis., 28, 225–232 (1996).
Kim, K. H. and Lim, S. Y., Validation of enzyme immunoassay for the quantitative measurement of human IgG antibodies specific for Haemophilus influenzae type b capsular polysaccharide. Korean J. Pediatr., 50, 143–150 (2007).
Kim, K. H., Lee, H., Chung, E. H., Kang, J. H., Kim, J. H., Kim, J. S., Lee, H. J., Oh, S. H., Park, E. A., and Park, S-E., Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants. J. Korean Med. Sci., 23, 929–936 (2008).
Lee, H. J., Epidemiology of invasive Haemophilus influenzae infections and vaccine policy in Korea. Korean J. Pediat. Infect. Dis., 6, 53–68 (1999).
Losonsky, G. A., Santosham, M., Sehgal, V. M., Zwahlen, A., and Moxon, E. R., Haemophilus influenzae disease in the White Mountain Apaches: molecular epidemiology of a high risk population. Pediatr. Infect. Dis., 3, 539–547 (1984).
Lottenbach, K. R., Granoff, D. M., Barenkamp, S. J., Poweres, D. C., Kennedy, D., Irby-Moore, S., Homan, S. M., and Mink, A. M., Safety and immunogenicity of Haemophilus influenzae type b polysaccharide or conjugate vaccines in an elderly adult populations. J. Am. Geriatr. Soc., 52, 1883–1887 (2004).
Santosham, M., Englund, J. A., Mcinnes, P., Croll, J., Thompson, C. M., Croll, L., Glezen, W. P., and Siber, G. R., Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants. Pediatr. Infect. Dis. J., 20, 931–940 (2001).
Toraño, G., Toledo, M. E., Baly, A., Fernandez-Santana, V., Rodriguez, F., Alvarez, Y., Serrano, T., Musachio, A., Hernandez, I., Hardy, E., Rodriguez, A., Hernandez, H., Aguilar, A., Sanchez, R., Diaz, M., Muzio, V., Dfana, J., Rodriguez, M. C., Heynngnezz, L., and Verez-Bencomo, V., Phase I Clinical Evaluation of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b in Human Adult Volunteers. Clin. Vaccine Immunol., 13, 1052–1056 (2006).
Ward, J. I., Margolis, H. S., Lum, M. K., Fraser, D. W., Bender, T. R.., and Anderson, P., Haemophilus influenzae disease in Alaskan Eskimos: characteristics of a population with an unusual incidence of invasive disease. Lancet, 13, 1281–1285 (1981).
Wenger, J. D., Pierce, R., Deaver, K., Franklin, R., Bosley, G., Pigott, N., and Broome, C. V., Invasive Haemophilus influenzae disease: a population-based evaluation of the role of capsular polysaccharide serotype. J. Infect. Dis., 165(S1), S34–35 (1992).
Yang, P. S., Seo, J. I., Noh, K. T., Ryu, J. H., and Hwang, K. G., Studies of the change of antibody titers after vaccination of Haemophilus influenzae PRP-T conjugate vaccine. J. Korean Pediatr. Soc., 45, 987–993 (2002).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kim, N., Choi, G., Lim, CY. et al. An open-label, single-arm, phase I study to evaluate the safety and immunogenicity of LBVH0101, a new Haemophilus influenzae type b tetanus toxoid conjugate vaccine, in healthy adult volunteers. Arch. Pharm. Res. 33, 919–924 (2010). https://doi.org/10.1007/s12272-010-0615-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-010-0615-5